Literature DB >> 22213126

Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3.

Ana Cecilia Rodríguez1, Mark Schiffman, Rolando Herrero, Allan Hildesheim, Concepción Bratti, Mark E Sherman, Diane Solomon, Diego Guillén, Mario Alfaro, Jorge Morales, Martha Hutchinson, Li Cheung, Sholom Wacholder, Robert D Burk.   

Abstract

Carcinogenic human papillomavirus (HPV) infections are very common after sexual debut and nearly all become undetectable ("clear") within a few years. Following clearance, the long-term risks of type-specific HPV re-appearance and subsequent risk of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) are not well defined. In the 7-year, population-based cohort study in Guanacaste, Costa Rica, we studied how often type-specific carcinogenic HPV infections re-appeared after clearance and how often re-appearance led to CIN2+. We considered 1,740 carcinogenic HPV infections detected by MY09/11 PCR among 2,805 women (18-91 years old, median 34) who were actively followed at 6- or 12-month intervals. We identified women with one or more type-specific HPV infections that cleared and re-appeared and further defined a subgroup of "definite clearance and re-appearance" (≥2 intervening negative results over a period of ≥1 year). We determined the absolute risk of CIN2+ among the different groups. p values are two-sided. Only 7.7% (81/1,052) of HPV-infected women had intervening negative results. Very few (3.7%, 39/1,052) had "definite clearance and re-appearance", of which 5.1% (2/39) subsequently persisted to a diagnosis of CIN2. There were zero CIN3+ lesions. Extremely few women (2/2,805 of women in our cohort) had a type-specific carcinogenic HPV infection clear, re-appear and lead to CIN2+. If confirmed, this argues against vaccination to avoid re-appearance that leads to precursor lesions and against the need of frequent HPV screening after initial negative results.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22213126      PMCID: PMC3356792          DOI: 10.1002/ijc.27418

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

1.  Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women.

Authors:  Ralph P Insinga; Gonzalo Perez; Cosette M Wheeler; Laura A Koutsky; Suzanne M Garland; Sepp Leodolter; Elmar A Joura; Daron G Ferris; Marc Steben; Darron R Brown; Elamin H Elbasha; Jorma Paavonen; Richard M Haupt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-06       Impact factor: 4.254

2.  Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity.

Authors:  Helen Trottier; Silvaneide Ferreira; Patricia Thomann; Maria C Costa; Joao S Sobrinho; José Carlos M Prado; Thomas E Rohan; Luisa L Villa; Eduardo L Franco
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

3.  A review of human carcinogens--Part B: biological agents.

Authors:  Véronique Bouvard; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi; Lamia Benbrahim-Tallaa; Neela Guha; Crystal Freeman; Laurent Galichet; Vincent Cogliano
Journal:  Lancet Oncol       Date:  2009-04       Impact factor: 41.316

4.  A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin.

Authors:  Ola Forslund; Annika Antonsson; Peter Nordin; Bo Stenquist; Bengt Göran Hansson
Journal:  J Gen Virol       Date:  1999-09       Impact factor: 3.891

5.  Development and duration of human papillomavirus lesions, after initial infection.

Authors:  Rachel L Winer; Nancy B Kiviat; James P Hughes; Diane E Adam; Shu-Kuang Lee; Jane M Kuypers; Laura A Koutsky
Journal:  J Infect Dis       Date:  2005-01-21       Impact factor: 5.226

6.  Natural history of cervicovaginal papillomavirus infection in young women.

Authors:  G Y Ho; R Bierman; L Beardsley; C J Chang; R D Burk
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

7.  A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women.

Authors:  Darron R Brown; Marcia L Shew; Brahim Qadadri; Nicole Neptune; Maria Vargas; Wanzhu Tu; Beth E Juliar; Timothy E Breen; J Dennis Fortenberry
Journal:  J Infect Dis       Date:  2004-12-10       Impact factor: 5.226

8.  Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.

Authors:  Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Concepción Bratti; Mark E Sherman; Diane Solomon; Diego Guillén; Mario Alfaro; Jorge Morales; Martha Hutchinson; Hormuzd Katki; Li Cheung; Sholom Wacholder; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2010-02-15       Impact factor: 13.506

9.  Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years.

Authors:  Paula González; Allan Hildesheim; Ana Cecilia Rodríguez; Mark Schiffman; Carolina Porras; Sholom Wacholder; Alfonso García Piñeres; Ligia A Pinto; Robert D Burk; Rolando Herrero
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-15       Impact factor: 4.254

10.  Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study.

Authors:  Marc T Goodman; Yurii B Shvetsov; Katharine McDuffie; Lynne R Wilkens; Xuemei Zhu; Pamela J Thompson; Lily Ning; Jeffrey Killeen; Lori Kamemoto; Brenda Y Hernandez
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

View more
  20 in total

1.  Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

Authors:  Daniel C Beachler; Aimée R Kreimer; Mark Schiffman; Rolando Herrero; Sholom Wacholder; Ana Cecilia Rodriguez; Douglas R Lowy; Carolina Porras; John T Schiller; Wim Quint; Silvia Jimenez; Mahboobeh Safaeian; Linda Struijk; John Schussler; Allan Hildesheim; Paula Gonzalez
Journal:  J Natl Cancer Inst       Date:  2015-10-14       Impact factor: 13.506

2.  Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study.

Authors:  Shitaldas J Pamnani; Staci L Sudenga; Dana E Rollison; Donna J Ingles; Martha Abrahamsen; Luisa L Villa; Eduardo Lazcano-Ponce; Yangxin Huang; Amy Borenstein; Anna R Giuliano
Journal:  J Infect Dis       Date:  2018-09-08       Impact factor: 5.226

Review 3.  Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.

Authors:  Daniel C Beachler; Gwendolyne Jenkins; Mahboobeh Safaeian; Aimée R Kreimer; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2015-12-21       Impact factor: 5.226

4.  Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women.

Authors:  Anne F Rositch; Anne E Burke; Raphael P Viscidi; Michelle I Silver; Kathryn Chang; Patti E Gravitt
Journal:  Cancer Res       Date:  2012-09-27       Impact factor: 12.701

5.  Concurrence of multiple human papillomavirus infections in a large US population-based cohort.

Authors:  Zihua Yang; Jack Cuzick; William C Hunt; Cosette M Wheeler
Journal:  Am J Epidemiol       Date:  2014-10-29       Impact factor: 4.897

6.  Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals.

Authors:  Lea Widdice; Yifei Ma; Janet Jonte; Sepideh Farhat; David Breland; Stephen Shiboski; Anna-Barbara Moscicki
Journal:  J Infect Dis       Date:  2013-01-14       Impact factor: 5.226

7.  Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Sepideh Farhat; Teresa M Darragh; Michael Pawlita; Denise A Galloway; Stephen Shiboski
Journal:  J Infect Dis       Date:  2013-04-18       Impact factor: 5.226

8.  Characterizing the temporal dynamics of human papillomavirus DNA detectability using short-interval sampling.

Authors:  Su-Hsun Liu; Derek A T Cummings; Jonathan M Zenilman; Patti E Gravitt; Rebecca M Brotman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-15       Impact factor: 4.254

9.  An Examination of HPV16 Natural Immunity in Men Who Have Sex with Men (MSM) in the HPV in Men (HIM) Study.

Authors:  Daniel C Beachler; Ligia A Pinto; Troy J Kemp; Alan G Nyitray; Allan Hildesheim; Raphael Viscidi; John Schussler; Aimée R Kreimer; Anna R Giuliano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-02-23       Impact factor: 4.254

Review 10.  Updating the natural history of human papillomavirus and anogenital cancers.

Authors:  Anna-Barbara Moscicki; Mark Schiffman; Ann Burchell; Ginesa Albero; Anna R Giuliano; Marc T Goodman; Susanne K Kjaer; Joel Palefsky
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.